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ΑΒSTRACT
DESIGN OF A TARGETED BACTERIAL DRUG DELIVERY VECTOR FOR
THE TREATMENT OF CANCER AND METASTASES
MAY 2014
CHARLES ALEXANDER SWOFFORD
B.S., NORTHWESTERN UNIVERSITY
PH.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Neil S. Forbes
Engineered Salmonella possess unique capabilities that make them ideal drug delivery
vectors for tumors. Targeted bacterial delivery of anticancer proteins has the ability to
overcome therapeutic resistance in tumors that limits the efficacy of chemotherapeutics.
In my doctoral research, I identified a protein-drug that can be expressed by bacteria and
rapidly kills cancer cells. I also created a density dependent switch that initiates gene
expression in tumors and prevents expression in healthy tissue. Combining these two
systems has created a potent anti-cancer system that targets tumors with minimal toxicity.

I cloned genes for five potential anti-cancer proteins into Salmonella. Supernatant from
cultures was applied to MCF-7 mammary carcinoma cells to identify proteins that 1)
were expressed, 2) secreted, and 3) rapidly killed cancer cells. Of the investigated
proteins, α-hemolysin from Staphylococcus aureus (SAH) was the most promising
because it secreted, caused trauma to cellular membrane, and induced oncosis in 18
minutes. After exposure for six hours, SAH decreased cell viability by 90%.

The

maximum death rate induced by SAH was a 7.1% reduction in cell viability per minute.
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Due to systemic toxicity, bacteria that constitutively express anti-cancer drugs would not
be an alternative to standard chemotherapy. To overcome this, I engineered Salmonella
to initiate gene expression using the lux quorum sensing system. Quorum sensing (QS)
allows bacteria to change gene expression based on differences in population density.
Because salmonella preferentially accumulate in tumors, a QS genetic circuit could create
an expression switch that only initiates in bacterial colonies in tumors. QS Salmonella
only expressed GFP in high-density colonies in vivo. Gene expression of colonies was
also dependent upon the radial distance of neighboring bacteria. At densities above
5x1010 cfu/g, 84% of the colonies whose neighbors were at an average radial distance less
than 103µm expressed GFP, whereas no colonies expressed GFP when their neighbors
were at radial distances greater than 108µm. A mathematical model correctly predicted
GFP expression in 93% of 84,213 QS colonies based on density and radial distance from
adjacent Salmonella. QS Salmonella will allow for targeted bacterial drug delivery to
tumors while minimizing systemic toxicity.
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CHAPTER 1
INTRODUCTION

Current cancer chemotherapeutic regimens have limited efficacy due to therapeutic
resistance, which decreases the success rate for treatment of late-stage cancer and
metastases (Brown and Giaccia, 1998; Jain, 1998; Tannock et al., 2002). This therapeutic
resistance can be explained by a number of factors including 1) intra-tumoral transport
limitations, 2) reduced susceptibility of quiescent cancer cells, and 3) protein pumps that
expel therapeutics from cells (Jain, 1999; Tannock, 2001; Tannock et al., 2002). The first
two factors can be explained by the overall architecture of most tumors. Tumors consist
of chaotic vasculature, large intercapillary distances, and variable blood flow (Helmlinger
et al., 1997; Jain et al., 1997; Vaupel et al., 1989) that in turn create regions of 1) highly
perfused, rapidly proliferating cells, 2) poorly perfused, quiescent cells, and 3) avascular,
necrotic or apoptotic cells (Sutherland, 1988; Sutherland and Durand, 1984). Due to
perfusion limitations in the two inner regions of a tumor, most blood-born
chemotherapeutics cannot diffuse the distance needed to achieve sufficient cytotoxic
concentrations (Cowan and Tannock, 2001; Davis and Tannock, 2002; Tannock, 2001;
Tannock et al., 2002). Furthermore, most chemotherapeutics target rapidly growing cells
and have limited efficacy against quiescent cells (Jain, 1999; Tannock, 2001; Tannock et
al., 2002). Since most of the tumor cannot be eradicated even after multiple courses of
chemotherapy, the surviving cancer cells can repopulate the tumor leading to recurrence
and metastases (Davis and Tannock, 2000; Davis and Tannock, 2002; Fidler et al., 2000).
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Bacterial cancer therapies can overcome the many limitations of chemotherapy because
they can actively transport into tissue, penetrate tumor tissue, and be genetically
engineered to translate and transcribe most proteins. Most cutting edge therapeutics,
including viruses, liposomes, and antibodies do not actively transport because they do not
expend energy. These therapeutics can be highly specific to cancer cells, but due to high
molecular weight, cannot penetrate deep into tumor tissue (Graff and Wittrup, 2003;
Pluen et al., 2001). Bacteria can be used in concert with traditional therapies to attack
both the quiescent cells and proliferating cells of a tumor thereby eradicating all living
tumor tissue as opposed to only the outer region.

The use of bacteria as a therapeutic device for cancer is not a completely novel idea.
Over the past 150 years, numerous patients have seen eradication of their tumors
following severe bacterial infection (Coley, 1891; Nauts et al., 1946; Nauts et al., 1953).
Furthermore, many different genera of bacteria have been shown to specifically
accumulate in tumors including Salmonella (Jain, 1998; Pawelek et al., 1997),
Clostridium (Lambin et al., 1998; Minton, 2003; Nuyts et al., 2002; Theys et al., 2001),
Bifidobacterium (Fujimori et al., 2002; Yazawa et al., 2001), and Escherichia (Yu et al.,
2004). In recent years, scientists have developed various strains of bacteria that have
potential therapeutic advantages and reduce toxicity to the host. Low et. al has developed
an msbB- and purI- mutant of S. typhimurium (VNP20009) that is non-pathogenic in
mice, pigs, and humans (Clairmont et al., 2000; Low et al., 1999; Low et al., 2004; Toso
et al., 2002). This strain preferentially accumulates in subcutaneous mouse tumors 2000fold more than in the liver and spleen (Mei et al., St Jean et al., 2008). In addition, this
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strain also retards tumor growth and prolongs survival of tumor-bearing mice (Clairmont
et al., 2000; Low et al., 1999; Luo et al., 2001; Minton, 2003). Initial clinical trials
further showed that VNP20009 could be tolerated at a high dose and able to effectively
colonize human tumors (Nemunaitis et al., 2003; Toso et al., 2002). These trials suggest
that VNP20009 would be an ideal candidate strain for use in a bacterial cancer therapy.

Bacterial targeting differs between obligate and facultative anaerobes. Clostridium and
Bifidobacterium are obligate anaerobes and Salmonella and Escherichia are facultative
anaerobes. Obligate anaerobes cannot survive in oxygenated environments and therefore
only grow in hypoxic regions of tumors (Lambin et al., 1998; Minton, 2003). While
obligate anaerobes are effective at targeting and accumulating in hypoxic regions of
tumors, they are ineffective at targeting smaller tumors and micro-metastases. This is
due to the fact that smaller tumors have not grown to a size large enough to support a
necrotic, hypoxic center. Facultative anaerobes, on the other hand, have been shown to
effectively colonize tumors and metastases smaller than 200µm in diameter by more
complicated means of targeting.

Several possible mechanisms include: chemotaxis

toward compounds produced by tumors, preferential growth in tumor tissue, and
protection from clearance by the immune system in the poorly perfused environment of
tumors (Sznol et al., 2000).

Other than the ability to target tumors and metastatic sites, an effective bacterial therapy
must also deliver anticancer drugs to the cancerous site without increasing systemic
toxicity effects within the patient. This work aims to solve this problem in two steps by:
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i)

screening bacterial toxins that can effectively secrete out of VNP200010
and extracellularly kill cancer cells quickly and efficiently.

ii)

developing a gene triggering strategy that will induce drug expression only
within tumors and metastases while remaining repressed in healthy tissue
environments.

Targeted bacterial delivery of anticancer proteins has the ability to overcome therapeutic
resistance in tumors that limits the efficacy of chemotherapeutics. The ability of bacteria
to specifically target tumors allows for delivery of aggressive proteins that directly kill
cancer cells and cannot be administered systemically. However, few proteins have been
tested for this purpose. To identify effective molecules, we systematically sorted proteins
that have been shown to cause mammalian cell death. The genes for five proteins were
selected and cloned into E. coli and Salmonella. Supernatant from cultures of the
transformed bacteria was applied to flasks of MCF-7 mammary carcinoma cells to
identify proteins that 1) were expressed, 2) secreted, and 3) rapidly killed cancer cells.
Time-lapse images were taken to visualize mammalian cell morphology. Of the
investigated proteins, α-hemolysin from Staphylococcus aureus (SAH) was the most
promising because it was secreted, caused trauma to cellular membranes, and induced
oncosis in 18 minutes. After exposure for six hours, SAH decreased cell viability by
90%. In comparison, the positive control, Pseudomonas aeruginosa exotoxin A (PEA),
required 11 days to achieve a similar effect, when administered at 3,000 times its LC50.
The maximum death rate induced by SAH was calculated to be a reduction in cell
viability of 7.1% per minute, which was 200-fold faster than the PEA control. Two
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proteins, Dermonecrotic Toxin and Phospholipase C were active when extracted from the
bacterial cytoplasm but were not secreted. This investigation revealed for the first time
SAH as a potent anticancer drug for delivery by bacteria because of its ability to be
secreted in a fully functional form and aggressively kill cancer cells.

Due to low-level bacterial counts in healthy tissue, bacteria that constitutively express an
anti-cancer drug, such as SAH, would not be an alternative to standard chemotherapy.
Because Salmonella preferentially accumulate in tumors, we have engineered Salmonella
to switch on protein expression in response to high density using the lux quorum sensing
(QS) system. Fluorescence and density were measured in vitro and in a tumor-on-a-chip
device. QS Salmonella were injected into 4T1 tumor-bearing mice to quantify protein
expression in vivo using immunofluoresence. At low densities, 3% of QS colonies
expressed GFP compared to 41% of constitutive colonies and show statistically similar
expression levels at densities above 4.2x1010 cfu/g. GFP expression from QS colonies
was also dependent upon the radial distance of neighboring bacteria. At densities above
5x1010 cfu/g, 84% of colonies whose neighbors were at an average radial distance less
than 103µm expressed GFP. No colonies expressed GFP when their neighbors were at
radial distances greater than 108µm.

A mathematical model of AI-1 concentration

accurately predicted GFP expression in 93% of 84,213 QS colonies. It also showed that
GFP expression had a sigmoidal relationship with density and an inverse relationship
with the average radial distance of adjacent Salmonella. These results suggest that QS
Salmonella will allow for targeted bacterial drug delivery to tumors and metastases while
minimizing the risk of potentially harmful drugs reaching healthy tissue.
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CHAPTER 2
IDENTIFICATION OF STAPHYLOCOCCUS AURUES α-HEMOLYSIN AS A
PROTEIN DRUG THAT IS SECRETED BY ANTICANCER BACTERIA AND
RAPIDLY KILLS CANCER CELLS

2.1 Introduction
Current cancer chemotherapeutic regimens have limited efficacy due to therapeutic
resistance (Davies and Hiscox, 2011). Resistance is caused by intra-tumoral transport
limitations, reduced susceptibility of quiescent cancer cells, and protein pumps that expel
therapeutics from cells (Jain, 1998; Minchinton and Tannock, 2006; St Jean et al., 2008).
For example, in triple negative breast cancer (TNBC), a lack of known specific
therapeutic targets limits treatment options and reduces rates of pathologic complete
response (pCR) to lower than 22% (Isakoff, 2010; Liedtke et al., 2008). Using bacteria
that produce therapeutic proteins could overcome multidrug resistance. Anticancer
bacteria have already been shown to selectively accumulate in tumors 10,000-fold higher
than any other organ in mice while showing no signs of toxicity to the host (Forbes et al.,
2003; Ganai et al., 2009). In addition, anticancer bacteria actively penetrate tissue and
target distant metastases (Ganai et al., 2011; Kasinskas and Forbes, 2006; Kasinskas and
Forbes, 2007; Loeffler et al., 2008; Nuyts et al., 2001a). Native bacterial toxicity has been
shown to regress tumors and increase survival in multiple studies, but bacteria alone are
unable to completely eliminate tumors (Chen et al., 2009; Jia et al., 2007; Lee et al.,
2008; Low et al., 1999; Luo et al., 2001; Nagakura et al., 2009; Pawelek et al., 1997;
Thamm et al., 2005; Theys et al., 2006; Zhao et al., 2007). Engineering bacteria to secrete
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anticancer proteins has the potential to improve therapeutic efficacy and localize high
concentrations of drugs within tumors and metastatic sites. Identifying an anticancer
protein that both kills cancer cells and can be delivered by bacteria will be essential to
create a bacterial therapy that can efficiently eliminate tumors and metastases.

An effective protein for bacterial cancer therapy must 1) be easily transcribed and
translated by bacteria, 2) be secreted, 3) be extracellularly active, and 4) rapidly kill
cancer cells (Figure 2.1). Bacteria must be able to continuously produce and secrete the
protein for an extended period of time to overcome systemic clearance and maintain a
lethal concentration within the tumor site (Forbes, 2010). Continuous production would
also promote diffusion to tumor regions distal from bacterial colonies. The protein must
also be extracellularly functional once secreted from bacteria, as bacteria accumulate in
the extracellular space of dying tumor tissue (Kasinskas and Forbes, 2006; Kasinskas and
Forbes, 2007). Pore-forming proteins are attractive candidates because the majority act
externally on cells and do not require endocytosis (Panchal et al., 2002). The protein must
also be able to kill cancer cells at a concentration that can be maintained by bacterial
secretion. Many toxins derived from bacteria possess the ability to kill cancer cells but
few have been implemented with bacterial drug delivery. To date, Cytolysin A is the only
bacterial toxin that has been explored for delivery by anticancer bacteria (Jiang et al.,
2010; Nguyen et al., 2010; Ryan et al., 2009). Because of their potential, more proteins
must be identified.
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Bacterial toxins can be grouped into seven families based on their mode of action: 1)
pore-forming toxins, 2) ADP-ribosylating toxins (ADPRTs), 3) glycosylating and
deamidating toxins, 4) oxidoreductases, 5) cytolethal distending toxins (CDTs), 6)
neurotoxins, and 7) superantigenic toxins. Approximately 35% of all toxins are poreformers (Alouf and Popoff, 2006). These toxins create pores that disrupt and destroy
cellular membranes and induce cell swelling and lysis (Bischofberger et al., 2009). ADPribosylation toxins (ADPRTs) interrupt G-protein mediated signal transduction pathways
by transferring the ADP-ribose moiety of β-NAD+ to GTP-binding proteins (Wolf and
Elsässer-Beile, 2009). These pathways are involved in cell proliferation, tissue
differentiation, signal transduction, protein synthesis, protein translocation, vesicular
trafficking, and cytoskeleton structure. Glycosylating and deamidating toxins disrupt the
actin cytoskeleton of cells by modifying GTPases into an active or inactive form. This
results in the deterioration of the epithelial and endothelial barrier, leaving cells
vulnerable to pathogen proliferation (Aktories, 2011). Cytolethal distending toxins
(CDTs) induce DNA double-strained breaks and apoptosis (Lemichez and Barbieri,
2013). These toxins have structural and functional homology to mammalian DNase I
(Elwell and Dreyfus, 2000). Azurin is an oxidoreductase produced by bacteria that
possesses the unique ability to form a complex with tumor suppressor p53, increasing its
intracellular concentration and inducing apoptosis (Yamada et al., 2004). Neurotoxins
and superantigenic toxins specifically target neural and immune cells, respectively.

Viable protein candidates must have specific attributes to be useful for bacterial
cancer therapy. Candidates should be short, have few subunits, and contain minimal rare
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codons in their DNA gene sequence. Shorter proteins have higher production rates
because of fast folding kinetics and ease of secretion (Baneyx and Mujacic, 2004). Larger
proteins and proteins with multiple subunits often require molecular chaperones to aid in
secretion (Bogumil and Dagan, 2012). Heat-stable enterotoxin, for example, requires the
periplasmic enzyme DsbA to complete its folding (Peek and Taylor, 1992). These
chaperones would have to also be engineered into a bacterial vector to enable formation
of a functional protein. A protein with a high number of rare codons in its DNA gene
sequence will increase burden on the bacterial cell and slow protein translation (Rocha
and Danchin, 2004).

To identify a payload for bacterial therapy, we analyzed all protein toxins and tested the
most promising in vitro. Proteins were selected using a systematic method based on
prevalence in the literature, size, number of rare codons, and protein structure. Selected
proteins were inserted into a regulated cloning vector and transformed into an attenuated
Salmonella cancer vector VNP20009 (Low et al., 1999). An integrated assay involving
both bacterial and mammalian cell culture was used to screen the translation, secretion,
and killing ability of each protein. Cell morphology was observed over time using timelapse microscopy. Dose response curves were determined using a cell viability assay. The
proteins identified in this study could be used against resistant tumors and metastases that
were previously untreatable. Ultimately, combining these proteins with a bacterial
delivery system will allow for localized expression of a broadly effective anticancer drug
specifically within tumors.
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Large Toxin
Multiple Subunits

+

Small Toxin

Toxin

pBAD

Membrane Disruption

Secretion

+

Cancer Cell

+

Internalization

Cell Death

Figure 2.1 Ideal characteristics of a bacterially delivered protein for cancer therapy.
An ideal toxin should be small, secrete out of bacteria, and act externally on cancer cells
to cause death, either through membrane disruption or unassisted internalization into
cells.
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2.2 Materials and Methods
2.2.1 Protein selection
A systematic approach was used to identify proteins that would be used for testing in
vitro. First, proteins were separated into classes based on their mode of action. A subset
of proteins from each family was selected based on their prevalence in the literature,
which was quantified by the number of papers that were returned on PubMed
(www.pubmed.gov) after a keyword search for each toxin. Families of proteins were
eliminated based on cellular targets and number of subunits. Proteins within each family
were ranked based on their size and length/rare codon ratio. Smaller proteins and proteins
with high length/rare codon ratios were favored. Finally, proteins that were native to
gram-negative bacteria were favored because the cancer vector VNP20009 is also gramnegative.

2.2.2 Bacterial strains and plasmids
All plasmids were derived by inserting toxin genes into the two multiple cloning sites
downstream of the PBAD promoter in pBAD_MycHis (Figure 2.2). The pBAD_MycHis
plasmid consists of the medium copy ColE1 origin, the ampicillin resistance gene, the
araC gene and the PBAD promoter used to express the toxins in response to induction with
L-arabinose

(Guzman et al., 1995). Multiple cloning sites allowed for easy insertion of

multiple genes from different species (Table 2.1). Genes were all cloned out of their
respective organisms using a genomic DNA purification kit (Promega, Fitchburg, WI).
Restriction enzymes were all from New England Biolabs (Ipswich, MA).
11"

Staphylococcus aureus alpha-hemolysin (SAH) was cloned from Staphylococcus aureus
strain MW2, which was a gift from Dr. Voyich-Kane lab at Montana State University.
Dermonecrotic Toxin (DNT) was cloned from Bordetella pertussis strain Tohama I,
which was a gift from Dr. Stibitz at the Center for Biologics Evaluation and Research in
Bethesda, MD, USA. Pseudomonas Exotoxin A (PEA), Azurin, and Phospholipase C
(PLC) were cloned from Psuedomonas aeruginosa strain PAO1, which was a gift from
Dr. Pastan at the National Cancer Institute in Bethesda, MD, USA. Created plasmids
were transformed into both E. coli strain DH5α and Salmonella typhimurium strain
VNP20009.

2.2.3 Assay of protein efficacy
Single colonies of pBAD-PEA, pBAD-SAH, pBAD-PLC, pBAD-DNT, pBAD-Azurin,
and a control of pBAD-MycHisA were grown in Luria-Bertani (LB) media (Thermo
Fisher Scientific, Waltham, MA) supplemented with 100 ng/µL ampicillin overnight at
37˚C and shaken at 225 rpm. Samples were diluted 1:100 into fresh media, grown to midlog phase (OD600 ≈ 0.5), and were induced with 0.02% w/v L-arabinose for 4 hours to
induce toxin production. Bacterial cells were pelleted by centrifugation and separated for
lysis and supernatant extraction.

Supernatant fractions were purified with a 0.22 µm-filter and then concentrated 10X by
centrifugal ultrafiltration (Millipore, Billerica, MA, USA). A 10X dilution of the
concentrated supernatant was considered a co-culture equivalent concentration. Pellets
were resuspended and incubated for 30 minutes in 500 µL water containing 1X halt
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protease inhibitor cocktail (Thermo), 12.5 units/mL of dnaseI (Thermo), and 25 µg/mL of
lysozyme (Thermo). After incubation, pellets were transferred to 2 mL centrifuge tubes
with 600 µm glass beads. These samples were alternately vortexed for one minute and
incubated on ice for one minute, for ten cycles. One mL of water was then added,
vortexed briefly, and centrifuged for three minutes. The lysis supernatant was removed
without disturbing the glass beads.

MCF-7 human mammary carcinoma cells (American Tissue Type Collection, Manassas,
VA, USA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM); (SigmaAldrich, St. Louis, MO) containing 10% Fetal Bovine Serum (FBS); (Atlanta Biologicals,
Lawrenceville, GA) at 37˚C and 5% CO2. Cells were seeded at 2,500 cells/well into 96well plates and allowed to adhere to the culture surface for 24 hours. The media was
aspirated and replaced with treatment media consisting of 90% DMEM/FBS and either
10% phosphate-buffered saline (PBS), PEA toxin at 50 ng/mL, cell lysate, or a co-culture
equivalent of supernatant. This dilution allowed for protein levels equivalent to direct coculture without having bacteria in mammalian culture. Each treatment media application
was replicated in eight wells.

The comparison of bacterially produced SAH to an SAH standard was performed with
MCF-7 cells. Cultures of bacteria containing pBAD-SAH or pBAD-MycHis were
induced for four hours after reaching an OD600 of 0.5. Mammalian cells were seeded at
7,500 cells/well and treated with 100µl media containing a co-culture equivalent of
bacterial supernatants or 500ng/ml pure SAH (Sigma) for one hour.
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After 72 hours, transmitted light images (730.43µm x 556.52µm) were acquired by light
microscopy using an inverted microscope (Olympus, Center, Valley, PA). Cell viability
was

measured

by

(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfophenyl)-2H-tetrazolium) (MTS) assay (Promega, Madison, WI). Treatment medium
was replaced with 100 µl DMEM/FBS plus 20 µl MTS reagent and incubated for one
hour at 37˚C for color development. Absorbance was measured at 490 nm (Bio-Tek
Instruments, Winooski, VT). Relative survival values are reported as measured
absorbance normalized by PBS controls.

2.2.4 Protein expression analysis
Lysis and supernatant fractions from bacteria transformed with pBAD-PEA and pBADSAH were boiled with 4X Laemmli reducing buffer (Boston BioProducts, Ashland, MA)
for 5 minutes and run on SDS-PAGE for 45 minutes at 200 V. Proteins were transferred
to nitrocellulose membranes that were blocked with 5% milk in tris-buffered saline
containing 0.2% tween-20 (TBST) for one hour at room temperature. PEA samples were
probed with a 1:1000 dilution of rabbit anti-PEA (Sigma-Aldrich) overnight at 4˚C,
washed 3 times in TBST, probed with a 1:1000 dilution of polyclonal horseradish
peroxidase

(HRP)-conjugated

anti-rabbit

polyclonal

antibody

(R&D

Systems,

Minneapolis, MN) for one hour at room temperature, and washed three times in TBST.
SAH samples were probed with 1:1000 sheep anti-SAH polyclonal antibody (Abcam,
Cambridge, MA) overnight at 4˚C, washed three times in TBST, probed with a 1:1000
HRP-conjugated, donkey anti-sheep polyclonal antibody (R&D Systems) for one hour at
room temperature, and washed three times in TBST. To visualize and image the
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immunoblot, 4-chloro-1-naphthol/3,3’-diaminobenzidine (CN/DAB); (Thermo) was used
for chromogenic detection of HRP.

2.2.5 Dose response to SAH
Dose response curves were generated for three concentrations of PEA over the course of
three days and four concentrations of SAH over the course of six hours. For three-day
dose response of PEA, MCF-7 cells were seeded at 2,500 cells/well, grown for 24 hours,
and then the media was aspirated and replaced with DMEM/FBS containing 0, 5, 50, 500,
5,000, or 50,000 ng/mL of PEA toxin (Sigma-Aldrich). After one, three, or five days, cell
viability was measured after a one-hour treatment with MTS. The growth rate of MCF-7
cells was calculated by exponential regression of the PBS control cultures and used to
extrapolate initial cell count at day zero. Cell viability was normalized to this value.

For the six-hour dose response of SAH, cells were seeded at 7,500 cells/well, grown for
24 hours, and then the media was aspirated and replaced with dilutions of 10X
concentrated SAH supernatant in DMEM/FBS. The supernatant was applied in relation to
bacterial co-culture at a dilution of 1:1, 1:2, 1:10, and a 1:100. After zero, two, four, or
six hours, cell viability was measured using a one-hour treatment with MTS. Relative
viability was determined by normalizing the absorbance to PBS controls. The 1:1 dilution
culture was visualized over time using epifluorescent microscopy. Time-lapse transmitted
images were captured every three minutes and tiled using a macro in IPLab (BD
Bioscience, Rockville, MD).
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The cell death rate induced by SAH was estimated by fitting dose response data to a
saturation function:

dCCell
= − µd CCell
dt

(1)

where

€

(2)
and the loss of free SAH from the system:

dCCell
= −kinc CSAH
dt

(3)

Here CCell is the relative survival of MCF-7 cells exposed to SAH, CSAH is the relative

€

concentration of SAH in bacterial supernatant, µd is the cell death rate, µmax is the
maximum cellular death rate, K is the relative SAH concentration at which cellular death
rate is half of the maximum, and kinc is the rate constant for SAH incorporation into
cellular membranes. Cellular growth was not included because of the short time scale.

The cell death rate for PEA was estimated by fitting the dose and rate data to a saturation
function:
(4)
where
(5)
Here Ccell is the relative survival of MCF-7 cells exposed to PEA, CPEA is the
concentration of PEA, µg is the cell growth rate, µd is the cell death rate, µmax is the
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maximum cellular death rate, and K is the PEA concentration at which cellular death rate
is half of the maximum. Cell growth rate, µg, was estimated by fitting the rate data of
control MCF-7 cells (not exposed to PEA) to the equation:
(6)

2.2.6 Cell death and membrane permeability
MCF-7 cells were seeded at 7,500 cells/well, grown for 24 hours. Media was aspirated
and replaced with either PBS or a 1:1 dilution of 10X concentrated supernatant from an
induced or uninduced culture of pBAD-SAH in DMEM/FBS. The media was
supplemented with a 1:800 dilution of ethidium homodimer (EtHd; Invitrogen, Carlsbad,
CA). After six hours, transmitted and red fluorescent images were captured within each
well. The total number of cells was counted by eye using the transmitted images and cells
were considered dead if they contained EtHd in the red fluorescent images.

2.2.7 Efficacy of SAH against resistant breast cancer
Three mammary carcinoma cell lines, BT-549, SkBr3, and MDA-MB-231, a generous
gift from Dr. Peyton at the University of Massachusetts Amherst, were cultured in
DMEM/FBS. Cells were seeded at 7,500 cells/well into 96-well plates and allowed to
adhere to culture surfaces for 24 hours. The media was aspirated and replaced with
treatment media consisting of 90% DMEM/FBS and either 10% phosphate-buffered
saline (PBS), or a co-culture equivalent of supernatant from pBAD-MycHis or pBAD-
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SAH. After six hours, cell viability was measured using a one-hour treatment with MTS.
Relative viability was determined by normalizing the absorbance to PBS controls.

2.2.8 Statistical Methods
Data are reported as mean ± standard error. Hypothesis testing was performed using
Student’s t-test with significance determined by P < 0.05.
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5’ MCS
(NheI or SacI)

PBAD

Toxin

araC

3’ MCS
(HindIII)

pBAD-Toxin
5011 bp
pBR322
Amp

Figure 2.2 Bacterial vector that can produce a toxin after direct induction with Larabinose. Plasmid contains the ampicillin resistance gene, the pBAD promoter that
responds to arabinose, the araC regulator gene, and the gene encoding the desired toxin.
Multi-cloning sites (MCS) at the 5’ and 3’ ends were used to insert toxin genes.
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Table 2.1 Toxin Cloning Summary
Table 2. 1 - Toxin Cloning Summary
Restriction
Gene
Species
Genome
Primers
Sites
CCATGGGGAAAACACGTATAGTCAGCTCAGTAAC NcoI
SAH S. aureus
MW2
GCAAGCTTATTTGTCATTTCTTCTTTTTCCCAAT
HindIII
ATGGATCCGAGCTCGATGCACCTGACAC
SacI
PEA
P. aeruginosa PAO1
AGAGAGAGAAGCTTTTACTTCAGGTCCT
HindIII
ATGAGCTCTGTGGATAAAGATGAATCGGCATT
SacI
DNT B. pertussis Tohama I GCAAGCTTGACCGGCGCCGGAAA
HindIII
ATGAGCTCGACCGAAAACTGGAAATTCC
SacI
PLC
P. aeruginosa PAO1
ATAAGCTTTCAGCGTTGCAGCAGGCG
HindIII
CATTACCATGGCTGCCGAGTGCTCGGT
NcoI
Azurin P. aeruginosa PAO1
GCATCTAAGCTTTCACTTCAGGGTCAGGGTGC
HindIII
Bold Letters Indicate Location of Restriction Site
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2.3 Results
2.3.1 Determination of toxin candidates for bacterial anticancer therapy
Four classes of bacterial proteins were considered as candidates for bacterial cancer
therapy (Table 2.2). Two classes, neurotoxins or superantigenic toxins, were excluded
due to their specificity for noncancerous cell types: neurons or leukocytes. Pore-forming
toxins were considered attractive candidates due to their ability to act extracellularly on
cells and do not require internalization. Cytolethal distending toxins (CDTs) were
eliminated because all proteins in this family consisted of three distinct subunits.

Using a systematic approach, five toxins were identified (Table 2.3). Two toxins,
Staphylococcus aureus alpha-hemolysin (SAH) and phospholipase C (PLC), were poreforming proteins. The other three were in three different classes, which ensured that
many mechanisms were investigated. Four of the proteins had been previously studied as
cancer therapies (Table 2.3). Most of the toxins were short compared to their group,
ranging from 149 aa to 1461 aa (Table 2.2). SAH was one of the few pore-forming
proteins that was small and did not contain multiple distinct subunits (Table 2.2).
Dermonecrotic toxin (DNT) had the highest length/rare codon ratio in the glycosylating
and deamidating protein class (Table 2.2). PLC, a pore-forming protein, had a high
length/rare codon ratio and did not contain multiple subunits. Pseudomonas Exotoxin A
(PEA) is one of the most well-studied proteins and has been investigated previously as a
cancer therapeutic. Azurin had the unique ability to increase the tumor suppressor p53
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within cells and induce apoptosis. It was also small in size and lacked rare codons (Table
2.3).

2.3.2 Screen for protein efficacy
Two proteins, PEA and SAH, were secreted out of bacteria and killed MCF-7 mammary
carcinoma cells in vitro (Figure 2.3). Supernatant from PEA and SAH producing strains
significantly decreased cancer cell survival (P<0.05) compared to an empty vector control
after a 72 hour exposure (Figure 2.3A). The empty vector control consisted of bacteria
containing the pBAD_MycHis plasmid that did not contain any toxin gene. PEA showed
a six-fold decrease in cell survival compared to the vector control and SAH decreased
cell survival by 80-fold. SAH supernatant was eight times better at decreasing cell
survival than the 50 ng/mL PEA positive control (P<0.05). This concentration is above
the reported LC50 value of 17 ng/mL for PEA (Kuan et al., 1994). PEA, secreted from
bacteria, did not reduce survival as well as the positive control (P<0.05). Supernatant
from the empty vector control did not reduce cell survival when compared to PBS alone.
Supernatant from all other toxin producing strains showed little to no effect at reducing
cell survival (Figure 2.3A).

Bacterial cell lysate from PEA-, DNT-, and PLC producing strains significantly
decreased cancer cell survival (P<0.05) compared to lysate from the empty vector control
(Figure 2.3B). The lysate from the empty vector control also had a significant effect on
reducing cell survival compared to PBS (P<0.05). SAH bacterial cell lysate had no effect
on cancer cell survival compared to the control. None of the bacterial lysates had a
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significant effect on cell survival when compared to the positive control. Bacteria with
pBAD-SAH was the only culture that did not exhibit growth over the course of the four
hour L-arabinose induction period (Figure 2.3C). SAH and PEA were present in both the
cell lysate and supernatant (Figures 2.4A and 2.4B). Bacterially produced PEA was the
only toxin that showed a significant effect on cell survival in both the cell lysate and
supernatant. SAH showed a greater effect on cell survival than PEA in the supernatant
but did not show any effect in the lysate. DNT and PLC only showed a significant effect
on cell survival in the lysate but not in the supernatant.

Supernatant from a culture of pBAD-SAH bacteria reduced cell viability similarly to
500ng/ml of pure SAH (Figure 2.4C). Both were significantly less than the vector control
(pBAD-MycHisA; P<0.05). Based on this similarity, bacteria with pBAD-SAH, at an
OD600 of 0.5, produced approximately 6,700 molecules of SAH·bacterium-1·hr-1.

2.3.3 Cell morphology
Supernatant collected from pBAD-SAH and pBAD-PEA bacteria disrupted cellular
integrity and induced cell death in MCF-7 mammary carcinoma cells (Figure 2.5). In
cultures treated with PBS and vector supernatant controls, cellular integrity remained
intact for more than three days. Nuclei and organelles were present over the entire period
(Figures 2.5A, 2.5B). Cells treated with supernatant from pBAD-SAH and pBAD-PEA
shrunk and had detached cellular material (Figures 2.5C, 2.5D). There were no visible
signs of functional organelles or nuclei. The cells also lost their ability to adhere to both
other cells and the surface.
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2.3.4 Concentration and time dependence of SAH on cellular death
Supernatant from SAH-producing bacteria significantly reduced MCF-7 cell survival
compared to PEA controls (Figure 2.6). The different mechanisms of these toxins
affected the rate of cellular death. Pure supernatant from pBAD_SAH reduced cell
viability to 68% (P<0.05) in five minutes, and further reduced cell viability to 10% in six
hours (P<0.05, Figure 2.6A). Treatment for 72 hours reduced viability by 99% (Figure
2.3A). A two-fold dilution in supernatant concentration also reduced cell viability to 40%
after six hours (P<0.05). This reduction of viability was considerably faster than PEA
administered at levels higher than its reported LC50 values (Figure 2.6B). PEA
administered at concentrations higher than 50 ng/mL took five days to reduce cell
viability below 40% (P<0.05). At 50,000 ng/mL, a concentration almost 3,000-fold above
the LC50 value, PEA reduced cell viability to 17% in five days (P<0.05).

The dosage and time data for supernatant from SAH-producing bacteria was modeled
with a saturation function using equations (1) and (2) and an SAH uptake function using
equation (3) (Figure 2.7A). This method determined the maximum cell death rate, µmax, to
be a 7.1% reduction in viability per minute. The saturation constant, K, was found to be
0.14, indicating that 14% of the concentration in the bacterial supernatant would produce
half the maximum cell death rate. Based on the model, the SAH membrane incorporation
rate, kinc, was estimated to be a 7.8% reduction in SAH concentration per minute (Figure
2.7C). The dosage and time data for PEA was also modeled with a saturation function
using equations (4), (5), and (6) (Figure 2.7B). For PEA, µd was found to be a 0.03%
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reduction in viability per minute and K was found to be 5.99 ng/mL. Comparison of the
maximum cell death rates of SAH supernatant with pure PEA indicates that SAH
supernatant kills cells 200 times faster (Figure 2.7D). Based on the model, it would take
SAH supernatant from pBAD_SAH one hour to reduce cell viability to 15%, while cells
exposed to PEA at 50,0000ng/mL would require 225 hours to reduce cell viability by the
same amount.

Time-lapse images of MCF-7 mammary carcinoma cells show the rate of cellular death
after exposure to SAH supernatant (Figure 2.8). All cells exhibited signs of cellular
oncosis after 45 minutes (Figure 2.8A). MCF-7 cells began to die as early as twelve
minutes after exposure and complete membrane destruction took six minutes after onset
of death (Figure 2.8B). SAH caused the cells to swell 12 minutes after exposure, forcing
condensation of the cellular material to one side of the cell. Despite stresses on cells, no
formation of apoptotic bodies was observed, indicating that cells were not undergoing
apoptotic cell death.

After six hours of exposure to SAH supernatant, cellular coagulation and shrinkage was
observed (Figure 2.9). Treated cultures showed increased staining (P<0.05) by ethidium
homodimer (EtHd), a marker of permeabilized membranes and cell death (Figure 2.9).
Supernatant from induced bacterial cultures killed over 98% of the total cell population
after six hours (Figure 2.9B). Similarly, treatment with SAH supernatant for six hours
reduced the viability of multiple mammary carcinoma cell lines (P<0.05), including two
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TNBC cell lines, BT549 and MDA-MB-231, as well as a HER2+/ER-/PR- cell line,
SkBr3, compared to vector controls (Figure 2.10).
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Figure 2.3 Screen for protein drugs for bacterial therapy. A) Supernatant fractions
from bacteria expressing Staphylococcus aureus alpha-hemolysin (SAH) and
Pseudomonas Exotoxin A (PEA) significantly reduce cell viability after 72 hours
compared to the empty vector control (*, P<0.05). Cell viability was normalized by the
PBS control. SAH significantly reduced cell viability after 72 hours compared to a
standard of 50 ng/mL of PEA (positive control, PC; **, P<0.05). Other investigated
proteins are azurin, dermonecrotic toxin (DNT), and phospholipase C (PLC). B) Lysis
fractions from bacteria expressing PEA, DNT, and PLC significantly reduced MCF-7 cell
viability after 72 hours (*, P<0.05). The empty-vector control significantly reduced cell
viability compared to the PBS control (**, P<0.05). Values were normalized by the PBS
control. C) Change in optical density (ΔOD600) of bacterial cultures after 4-hour induction
with L-arabinose. SAH-expressing bacteria were the only culture that did not grow after
induction.
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Figure 2.4 Quantification of SAH production. A,B) Western blots of lysate and
supernatant from PEA-expressing (A) and SAH-expressing (B) bacteria. Both PEA and
SAH are produced and secreted. C) Supernatant from a co-culture equivalent of SAHproducing bacteria reduced cell viability compared to a vector control after a one hour
exposure (*, P<0.05). Resultant survival was similar to treatment with 500 ng/ml of pure
SAH.
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Figure 2.5 Images of MCF-7 cells after 72-hour exposure to toxins from bacterial
supernatant. A) Cells that did not receive any bacterial supernatant appear healthy. B)
Cells exposed to bacterial supernatant from the empty vector appear healthy. C) Cells
exposed to PEA bacterial supernatant have shrunk and appear dead. D) Cells exposed to
SAH bacterial supernatant have shrunk and appear dead. All scale bars are 50µm.
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Figure 2.6 Time and concentration dependence of MCF-7 cell viability after
exposure to SAH and PEA supernatant. A) Concentration dependence of MCF-7 cell
viability after 0.08, 2, 4, and 6-hour exposure to SAH-expressing bacterial supernatant
fractions. All dilutions greater than 1:100 showed significant reduction in cell death after
two hours of exposure (*, P<0.05). Pure supernatant and a 2X dilution of supernatant
showed a significant reduction in cell death after five minutes (*, P<0.05). B)
Concentration dependence of MCF-7 cell viability after one, three, and five-day exposure
to pure PEA toxin. All concentrations at 50 ng/mL or above showed a significant
decrease in cell viability after five days compared to PBS control on day one (*, P<0.05).
Cell viability was normalized to an extrapolated initial cell viability value using the
growth rate of the 0 ng/mL control.
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Figure 2.7 Model of survival response for SAH and PEA A) Model of survival
response for SAH. The maximum cell death rate, saturation constant and rate of SAH
loss were calculated to be µmax= 0.071 min-1, K=0.14, and kinc=0.078 min-1, respectively.
B) Model of survival response for PEA. The maximum cell death rate and saturation
constant were calculated to be µmax=0.0003 min-1 and K=5.99 ng/mL. C) SAH
concentration for different starting supernatant dilutions, based on the SAH model in
equations (1), (2), and (3). D) Comparison of SAH supernatant and PEA models over 6
hours. SAH supernatant is 200 times faster at killing cells than 50,000 ng/mL PEA.
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Figure 2.8 Time-lapse images of MCF-7 cells exposed to SAH-expressing bacterial
supernatants. A) MCF-7 mammary carcinoma cells undergo cell death in under 45
minutes after exposure to supernatant from SAH-expressing bacteria. Cells swelled and
contents condensed to one end of the cell. All scale bars are 150 µm. B) Once initiated,
oncosis took approximately six minutes. Each colored arrow (white, black and grey)
indicates a different cell undergoing oncosis.
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Figure 2.9 Quantification of Cell Death A) Ethidium homodimer (EtHd) staining of
cultures exposed to induced pBAD-SAH supernatant compared to an uninduced control.
B) Induced SAH supernatant killed 98% of the total cell population after six hours
compared to uninduced and PBS controls (*, P<0.05).
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Figure 2.10 Cell viability of mammary carcinoma cells treated with SAH.
Supernatant from pBAD-SAH bacteria reduced cell viability in two TNBC cell lines,
BT549 and MDA-MB-231, as well as the HER+/ER-/PR- cell line SkBr3. Cells were
exposed for six hours and compared to individual vector controls for each cell line (*,
P<0.05). Viability was normalized by the PBS control for each cell line.
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Table 2.2 Toxin Families
Table 2. 2 - Toxin Families
Class
1) Pore-Forming
2) ADP-Ribosylating
(ADPRT)
3) Glycosylating and
Deamidating
4) Oxidoreductases
(Redox)
5) Cytolethal
Distending Toxins
(CDT)

Paper Count
264-2532

Number of
Distinct
Subunits1
1-2

Number of Rare
Codons1
2-23

Length/Rare
Codons1
78.8-15.4

Sizes
(aa)1
71-1024

Intracellular

659-2228

1

9-13

59.4-49.2

12

Intracellular

65-516

1

29-75

50.4-17.1

535-639
10141461

1

Intracellular

793

1

0

N/A

149

24

Intracellular

17-287

3

7-12

58.3-33.9

1
1

32-110
1-11

40.3-11.8
22.8-234

270-700
12521315
152-251

Total
Number
117

Mode of Action
Extracellular

21

6) Neurotoxins
7
Intracellular
1170-2124
7) Superantigenic
39
Intracellular
72-1074
Bolded classes indicate the families of the selected toxins for in vitro studies
1
Data collected from the NCBI Protein Database http://www.ncbi.nlm.nih.gov/protein
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Table 2.3 Selected Toxins
Table 2. 3 - Selected Toxins
Toxin
Phospholipase
C (PLC)

Class

α-hemolysin
Pseudomonas
exotoxin A

Pore-forming
ADPRibosylating
Glycosylating
and
Deamidating

Dermonecrotic
Toxin (DNT)

Pore-forming

Organism
P. aeruginosa
(Gram-)
S. aureus
(Gram+)
P. aeruginosa
(Gram-)

Paper Count
348
906
2228

Previously
Considered for
Cancer Therapy
(Wang et al., 2012)
(Johansson et al.,
2008)
(Wolf and ElsässerBeile, 2009)

B. pertussis
65
No
(Gram-)
P. aeruginosa
(Bernardes et al.,
Azurin
Oxidoreductase (Gram-)
793
2013)
1
Data collected from the NCBI Protein Database http://www.ncbi.nlm.nih.gov/protein

36#

Number of
Rare Codons1

Subunits1

Length/Rare
Codons (aa/#)1

Size (aa)1

1

15

48.7

730

1

14

22.8

319

1

13

49.2

639

1

29

50.4

1461

1

0

N/A

149

2.4 Discussion
A screen of multiple bacterial toxins identified SAH as a candidate for bacterial
anticancer therapy. The goal of the screen was to identify proteins that were 1) easily
transcribed and translated by bacteria, 2) secreted, 3) extracellularly active, and 4) could
rapidly kill cancer cells (Figure 2.1). A streamlined process was used that tested the
ability of proteins to be secreted from bacteria and their efficacy against cancer cells. By
directly applying supernatant to cancer cells, any evidence of cell death indicated all three
processes: expression, secretion, and efficacy. In addition, any supernatant or lysis
fraction toxic to cancer cells indicated that the protein was produced in a functional form
and was active against mammalian cells when applied extracellularly. Of all cloned
proteins, only SAH and PEA showed a significant reduction in cell viability (Figure
2.3A). Furthermore, SAH was the only cloned protein that rapidly killed cells. Cell
viability dropped 85% in less than one hour (Figure 2.6A).

The results from the lysis experiment (Figure 2.3B) indicated that Salmonella were able
to express DNT and PLC but were unable to secrete these toxins into the supernatant.
While cell viability was reduced in the DNT and PLC lysis fractions, there was no effect
on cancer cells when exposed to the supernatant fraction. DNT and PLC from the lysate
killed cancer cells when added to culture medium (Figure 2.3B) indicating that the
proteins were functional and active when applied extracellularly. Azurin had no effect in
either the lysis fraction or the supernatant indicating that it was either not expressed or
was not extracellularly functional.
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SAH in the supernatant functioned differently from SAH in the cell lysate because of its
mechanisms of secretion and pore formation. The first 26 residues on the N-terminus of
SAH contains a signal sequence that is cleaved upon secretion (Dinges et al., 2000). Once
cleaved, monomers integrate into membranes of host cells and form cylindrical
heptameric pores that lyse eukaryotic cells. The now-exposed N-terminus extremity is
essential because it interacts with adjacent monomers when forming the pore mouth
(Vandana et al., 1997). SAH from the cell lysate could not induce cell death because the
secretion signal had not been cleaved from the N-terminus, which would have prevented
formation of the heptamer pores.

An important requirement for new cancer therapeutics is an ability to treat multidrug
resistant tumors and metastases. SAH has the ability to treat resistant cancers because it
indiscriminately kills cells. The mechanism is effective against multiple cell types
because SAH forms pores in the membrane and does not require endocytosis to be
effective (Berube and Bubeck Wardenburg, 2013). SAH was shown to reduce cell
viability in two TNBC cancer cell lines, BT549 and MDA-MB-231, as well as a
HER2+,ER-,PR- cell line, SkBr3 (Figure 2.10). When applied to MCF-7 cells (Figure
2.8), cellular membrane disruption caused swelling due to accumulation of water and
electrolytes forcing the cellular organelles to one side of the cell. These are all classic
signs of oncosis, cellular death due in part to disruption of ionic channels in the cell
membrane (Majno and Joris, 1995; Saraste and Pulkki, 2000). This form of cell death is
beneficial since it is induced by cellular trauma, as opposed to a pathway-mediated cell
death that can be cell-type specific.
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For the treatment of aggressive cancers, new therapeutics must kill cells faster than they
can replicate. SAH secreted from bacteria can reduce cell viability by 50% in 12 minutes
(Figure 2.6A). This is much faster than the doubling times of 0.8-1.2 days for many
TNBC cell lines in vitro (Yoon et al., 2002). PEA, at concentrations three orders of
magnitude above the reported LC50 value, required 82 hours to reduce cell viability by
the same amount. This suggests that aggressive cancers could not grow fast enough to
overcome continual production of SAH but could continue to grow even with high
concentrations of PEA. In culture, the SAH concentration was reduced due to
incorporation in the membrane of dying cells (Figure 2.7C). This decrease would not
occur within a tumor, where bacteria would continuously produce SAH and overcome
loss to cellular uptake. The rate of SAH production and its rate of killing would enable
the number of bacteria that typically colonize tumors (Ganai et al., 2011) to effectively
kill cells.

Results with this screen suggest that SAH and other potential proteins, previously
considered too dangerous for cancer therapy, should be reevaluated in the context of
bacterial drug delivery. While SAH has been researched in vitro as a method to overcome
cisplatin resistance in certain cancer cell types (Johansson et al., 2008), it has never been
considered a therapeutic in its own right due to the potential for high systemic toxicity.
Previous studies have shown that cells can reverse membrane damage after exposure to
SAH at low concentrations (Thelestam and Möllby, 1983). Attenuated bacteria can
provide the localized and persistent drug expression needed to prevent cells from
regenerating their membrane by constant exposure to the toxin. The ability of bacteria to
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localize to tumors could reduce the systemic effects of SAH while maximizing its
concentration at the target site (Ganai et al., 2009). Triggering strategies using a
combination of L-arabinose and quorum sensing could help to induce toxin expression
once bacterial localization has been achieved (Dai et al., 2012). In vitro screening of
bacterial toxins for bacterial cancer therapy has the potential to reveal new classes of
therapeutics that could be more effective against tumors and metastases than current
chemotherapeutics.

2.5 Conclusion
We have discovered SAH as a candidate for bacterial anticancer therapy after screening
proteins from seven different toxin families. SAH is produced and secreted out of
bacteria in concentrations that rapidly kill cancer cells. It acts externally on cells by
damaging cell membranes and inducing oncosis. Combining this potent toxin with the
targeted delivery capabilities of bacteria could greatly increase localized toxicity at tumor
sites.
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CHAPTER 3
QUORUM-SENSING SALMONELLA SELECTIVELY TRIGGER PROTEIN
EXPRESSION WITHIN TUMORS

3.1 Introduction
Engineering Salmonella to trigger protein expression specifically after tumor colonization
has the potential to solve a critical problem with chemotherapy.

Current cancer

chemotherapeutic regimens have limited efficacy due to therapeutic resistance, which
decreases the success rate for treatment of late-stage cancer and metastases (Brown and
Giaccia, 1998; Jain, 1998; Tannock et al., 2002), as well as inherent systemic toxicity,
which prevents the use of more aggressive dosage schemes (Sakhrani and Padh, 2013).
Salmonella are capable of overcoming these therapeutic limitations because they
preferentially accumulate in tumors, actively penetrate tumor tissue, and can be
engineered to produce anti-cancer drugs in situ (Forbes et al., 2003; Ganai et al., 2009;
Ganai et al., 2011; Kasinskas and Forbes, 2006; Kasinskas and Forbes, 2007; Loeffler et
al., 2008; Nuyts et al., 2001b). Due to systemic toxicity, however, Salmonella that
constitutively express an anti-cancer drug would not be an alternative to standard
chemotherapy, due to low-level bacterial accumulation in healthy tissue (Forbes et al.,
2003). Salmonella engineered to initiate anti-cancer drug expression using a tumorsensitive switch has the capability to both reduce systemic toxicity and allow for the use
of more aggressive therapeutics due to enhanced drug targeting.

Salmonella can be engineered to trigger protein expression in response to external cues
(Hoffman et al., 2008), but these signals are dependent on both diffusion and location of
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the tumor. Previous bacterial cancer studies have used external cues such as arabinose or
salicylate to induce drug transcription (Dai et al., 2012; Loessner et al., 2007; Nguyen et
al., 2010; Royo et al., 2007; Stritzker et al., 2007) in bacteria, but these methods are
inherently

more

difficult

because

small

molecules,

analogous

to

current

chemotherapeutics, cannot diffuse deep into tissue to trigger bacterial drug expression
(Foley et al., 1978; Loessner et al., 2007; Seri et al., 1996). Radiation has been suggested
as another possible trigger (Ganai et al., 2009; Nuyts et al., 2001a; Nuyts et al., 2001b),
but radiation-inducible promoters have high uninduced protein expression, possibly
leading to harmful effects in healthy tissue. Promoters that respond to hypoxia have also
been suggested as a potential triggering strategy (Arrach et al., 2008; Mengesha et al.,
2006; Ryan et al., 2009) but many micrometastases do not develop hypoxia that would
signal bacteria to initiate drug production.

Integrating nonpathogenic Salmonella with a QS genetic circuit would create a robust
expression switch that only turns on in bacterial tumor colonies (Figure 3.1A). Quorum
sensing (QS) is the ability of bacteria to change their gene expression based on changes
in population density (Waters and Bassler, 2005). Because Salmonella accumulate in
tumors at densities almost 10,000-fold higher than other organs (Forbes et al., 2003;
Ganai et al., 2009; Zhang et al., 2013), sensing changes in density would provide a switch
to distinguish between healthy and cancerous tissue.

Many bacterial populations

naturally sense density through QS systems. The lux QS system is used by the marine
bacterium Vibrio fischeri to induce the expression of genes required for bioluminescence
once it has colonized the gut of the Hawaiian squid Euprymna scolopes. This squid uses
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the light provided by the bacteria for counterillumination to mask its shadow and avoid
predation (Waters and Bassler, 2005). The lux QS system consists of two genes: LuxI
and LuxR (Figure 3.1B). LuxI synthesizes the autoinducer N-3(oxohexanoyl)homoserine
lactone, also known as AI-1.

LuxR, the transcriptional regulator, activates in the

presence of AI-1 and induces transcription by binding to the promoter PluxI (Fuqua et al.,
2001; Sitnikov et al., 1995). At low population density, low-level expression of LuxI
synthesizes AI-1, which freely diffuses out of cells. As the population density increases,
intracellular AI-1 activates LuxR, creating a positive feedback loop which increases the
production of any gene incorporated into the operon (Sitnikov et al., 1995). QS systems
have been used previously to trigger E. coli invasion into cancer cells (Anderson et al.,
2006).

To create a tumor-sensitive gene expression switch, we integrated the lux QS system and
a fluorescence reporter into attenuated Salmonella. We hypothesized that QS Salmonella
would (1) switch on gene expression in response to high bacterial density and (2) only
switch on gene expression in tumor tissue. Fluorescence and density were measured in
culture and compared to controls that constitutively expressed GFP. GFP expression was
measured in an in vitro tumor-on-a-chip device to assess if QS Salmonella turn on
expression within tissue. QS and constitutive Salmonella were injected into tumorbearing mice to quantify protein expression in vivo. Organ plating was used to quantify
bacterial colonization in tumors and livers. Immunofluorescence was used to quantify
the spatial distribution and density of bacteria and GFP expression within tumors. A
mathematical model was created to predict the density and distribution of bacteria needed

43#

to turn on protein expression within tumors. QS Salmonella will improve the use of
bacteria for the treatment of cancer by creating a sensitive switch that will express protein
therapeutics in tumors without toxic effects in healthy tissue.
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Figure 3.1 Schematic of QS bacterial drug delivery. A) QS Bacteria will only turn
on drug expression once they have colonized tumor tissue and sense an increase in their
localized density. B) The PluxI promoter controls one operon consisting of the genes
encoding for the LuxR, GFP, and LuxI proteins. LuxI produces the communication
molecule AI-1. The PluxI promoter responds to LuxR protein bound to AI-1. As the
density of bacteria increases, AI-1 concentration increases within the cell, creating a
positive feedback loop that increases transcription of the operon.
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3.2 Results
3.2.1 Quorum-sensing Salmonella behavior in vitro
Salmonella transformed with a quorum-sensing system using GFP as a reporter (QSGFP) turned on GFP expression only at high density in culture and in in vitro tumor
tissue (Figure 3.2). Salmonella were grown from colonies, diluted at either 0.5x108
cfu/mL (Diluted Low) or 5x108 cfu/mL (Diluted High) down to 105 cfu/mL, and then
their density and GFP expression was measured over time (Figure 3.2A). At densities
less than 0.5x108 cfu/mL, QS-GFP remained off compared to LB controls (Figure 3.2B;
P<0.05). Once a critical density threshold of 108 cfu/mL was reached, QS-GFP turned on
GFP expression. Constitutive controls linearly increased GFP expression with density
and had low-level expression at densities as low as 2.5x107cfu/mL (Figure 3.2B).

Diluting QS-GFP at high densities increased GFP expression levels but not the critical
density that switches on expression (Figures 3.2C-D). Both the Diluted High and Diluted
Low cultures turned off gene expression after dilution to 105 cfu/mL and turned on GFP
expression at 108 cfu/mL (Figure 3.2C). The Diluted High cultures, however, had a
higher GFP expression compared to the Diluted Low cultures at densities higher than
5x108 (P<0.05; Figure 3.2D). Because to this increase in GFP expression, all subsequent
experiments were cultured using the Diluted High cultured method.

QS-GFP only turned on GFP expression within high-density colonies in in vitro 3D
tumor tissue compared to controls (Figures 3.2E-F). Thirty-eight hours post bacterial
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injection, tumor tissue infected with QS-GFP exhibited pockets of GFP expression within
distinct bacterial colonies while the remaining tissue area contained no GFP expression
(Figure 3.2E). The tumor tissue infected with constitutive bacterial controls turned on
GFP expression throughout the entire tissue by 53 hours, indicating that bacteria colonize
the entire tissue. The area of affected tissue was greater in the constitutive controls than
QS-GFP (Figure 3.2F; P<0.05). QS bacteria expressing GFP were present in 45% of the
total tissue area after 53 hours compared to 97% area coverage for the constitutive
bacteria. The heterogeneity of the GFP expression within the tissues infected with QS
bacteria indicates a switch behavior between areas of low and high bacterial densities.

3.2.2 Quorum-sensing salmonella behavior in tumor-bearing mice
Mice injected with QS-GFP expressed GFP within high-density colonies in tumor tissue
and showed no sign of GFP expression within livers (Figure 3.3). 84,213 and 133,305
colonies of Salmonella were present in tumor tissue for QS and constitutive controls,
respectively, while no Salmonella or GFP was present in corresponding livers using
immunofluoresence (Figure 3.3A). Salmonella density was 2.21x106 cfu/g and 1.13x107
cfu/g in tumors and 2.49x104 cfu/g and 2.92x104 cfu/g in livers of both the QS and
constitutive Salmonella infected mice, respectively. (Figure 3.3B). There was, however,
no statistical difference between the QS and constitutive bacterial densities across livers
or across tumor tissue. In tumor sections of mice infected with QS-GFP, GFP colocalized with large colonies of bacteria (Figure 3.4A, i-iii) while no GFP co-localized
with small colonies (Figure 3.4A, iv-vi). In comparison, GFP expression co-localized
with colonies of constitutive controls, regardless of colony size (Figures 3.4A, vii-xii).
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QS Salmonella did not require an external inducer and GFP expression was observed in
tumor tissue as early as 9 days and as late as 24 days post injection.

At low densities, 41% of constitutive colonies express GFP compared to 3% of QS
colonies (P<0.05, Figure 3.4B). QS colonies begin to show statistically similar GFP
expression levels as low density constitutive colonies at densities above 4.2x1010 cfu/g
(P<0.05). The likelihood of a QS colony expressing GFP statistically increased from 4%
to 43%, once the density reached 4.2x1010 cfu/g (P<0.05, Figure 3.4C). In comparison,
the likelihood of constitutitve colonies expressing GFP statistically increased from 45%
to 72%, once the density reached above 4.2x1010 cfu/g (P<0.05).

No constitutive

colonies above a density of 4.8x1010 cfu/g were found in tissue.

3.2.3 Optimization of Density Calculations
To quantify the effect of density and spatial distribution of QS-GFP on GFP expression
within tissue, the average radial distance and the number of bacteria were counted within
circles of increasing radii surrounding the center of mass of each individual colony
(Figure 3.5). The total number of bacteria expressing GFP was calculated as a function
of bacterial density and fit to the sigmoidal function:

α=

& ρ − ρcrit )
1 1
+ tanh(
+
' σ *
2 2

(7)

where α is the fraction of bacterial colonies expressing GFP, ρ is the density of

€

salmonella within the circle, ρcrit is the critical density at which GFP expression occurs,
and σ represents how sensitive the quorum-sensing switch is to changes in density
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(Figure 3.5A). The percentage of colonies expressing GFP fit Eq. 1 with ρcrit = 4.97x1010
cfu/mL and σ = 2.72x1010 cfu/mL within a circle size of 125 pixels (161.3µm; Figure
3.5B). The majority of colonies below this critical density exhibited little to no GFP
expression while the majority of colonies above this critical density co-localized with
GFP in tissue. No colonies were found in tissue above a density of 5.65x1010 cfu/g but
the model infers that over 95% of colonies would express GFP at densities upwards of
9.01x1010 cfu/g.

To calculate the optimal circle size for density optimization, the density of Salmonella
surrounding each colony was calculated for circles ranging from a radius of 10 pixels
(12.904µm) to 200 pixels (258.08µm; Figure 3.5C). Varying the circle size around the
colony was important for determining the region in which bacteria interacted with their
neighbors. Circles that were too small can underestimate the total number of bacteria
interacting with the colony of interest while circles that were too large can overestimate
the number of bacteria interacting with the colony of interest. A circle with a radius of
125 pixels was used for further analysis because it minimized the standard error of the
fitted parameters ρcrit and σ to the data (Figure 3.5D). ρcrit and σ minimized at a circle
with a radius of 150 pixels (Figure 3.5E).

3.2.4 Effect of spatial distribution on GFP expression
At high densities, the percentage of colonies expressing GFP increases as the average
radial distance of neighboring colonies decreases from the colony of interest (Figure 3.6).
The number of Salmonella were counted for increasing annuli from each colony of
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interest and used to calculate the weighted average distance of all neighboring colonies
(Figure 3.6A). At densities above 5.28x1010 cfu/g, 84% of the colonies whose neighbors
were at an average radial distance less than 103µm expressed GFP while zero colonies
expressed GFP when their neighbors were at radial distances greater than 108µm
(P<0.05; Figure 3.6B).

Between this range, 58% of the colonies expressed GFP. At

densities below 5.28x1010 cfu/g, radial distance has no effect on GFP expression. Only
43% of colonies expressed GFP when neighbors were at a radial distance of 103µm or
less compared to the 84% seen at densities above 0.44 (P<0.05).

3.2.5 Mathematical Modeling of AI-1 production and diffusion in tumor tissue
AI-1 concentration in tumor tissue was mathematically modeled by a partial differential
equation that related AI-1 production to colony density and diffusion into infinite threedimensional space.

∂C D ∂ # 2 ∂C &
=
%r
(
∂t r 2 ∂r $ ∂r '

€

dC
= m˙ α
dt r =0

C r =∞ = 0

(8)

Here, C is the concentration of AI-1 and D is the diffusion coefficient of AI-1 in tissue.
€
€
The boundary conditions
state that AI-1 is produced by a release rate, m, and the fraction
of colonies expressing GFP, α, which is dependent on bacterial density (Eq. 7), which is
dependent on density ρ, and the concentration is zero far from the colony. This problem
is set up using the density of bacteria and the average radial distance of all the colonies
surrounding the colony of interest.

Neighboring bacteria are lumped together and

considered a point source at r=0, while the colony of interest is at the average radial
distance (r=ravg) away from the point source (Figure 3.7A). The analytical solution of Eq.
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2 is dependent on dimensionless distance r , time t , bacterial density ρ, and a
dimensionless parameter, Q, that relates AI-1 production, to diffusion.
C=

# r &
αQ
erfc%
(
r
$2 t '

€

€

(9)

Here, C , r , and t are dimensionless concentration (C/Cq), radius (r/rc), and time (
€

€

Dt
).
rc2

Cq is the minimum AI-1 concentration necessary to turn on GFP expression and rc is the
€
€
€ the relative
radius of the circle of interest. The dimensionless number, Q, describes
contributions of AI-1 production to AI-1 diffusion (

m˙
). The steady state solution
4 πDCq rc

of Eq. 3 is

α ( ρ )Q
C=
r

€

(10)

The model was assumed to be at steady state since all mice were sacrificed greater than 9

€

days post-injection, depending on the growth rate of the individual tumors. Q was
determined to be 1.1 by non-linear optimization and predicted the GFP expression in 93%
of individual QS colonies found in tissue. Q, which is greater than one, indicates that the
system is diffusion limited when α is equal to one. When α is below 0.68 (8.17x1010
cfu/g), the system becomes production limited as the product of α*Q falls below 1.
Mathematical modeling predicted that the AI-1 concentration decreases with distance
from the colony point source (Figure 3.7B). The concentration profiles increase
sigmoidally as the density of the source colony increases (Figure 3.7C). The density at
the colony would have to reach 8.17x1010 cfu/g to turn on a colony if it was at the very
edge of a 161.3µm circle.
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As the density decreases, the maximum radial distance at which neighboring colonies
expresses GFP, rq, increases in a sigmoidal shape (Figure 3.8A). At the critical density
predicted by Eq. 1 (ρcrit = 4.97x1010 cfu/g), rq is 87.1µm. Colonies that have a high
density and are packed tightly together are most likely to express GFP (Figure 3.8B, i).
The model predicts the differences in GFP expression between two colonies with the
same density and a 2µm difference in radial distance (Figure 3.8B ii,iii). The model also
predicts the difference between two colonies with the same radial distance and a 9.9x109
cfu/g difference in density (Figure 3.8B ii,iv). There was no colony below a density of
4.92x1010 cfu/g that had a radial distance small enough to be predicted as having GFP
expression.
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Figure 3.2 In vitro Behavior of QS Salmonella. A) QS cultures were grown to either
0.5x108 cfu/mL or 5x108 cfu/mL and then diluted to 105 cfu/mL. B) QS Salmonella only
expressed GFP at densities above 0.2 compared to constitutive controls (*, P<0.05). C)
Low dilution and high dilution cultures only showed significant expression compared at
densities above 0.2 (*, P<0.05). D) High dilution cultures showed a significant increase
in expression compared to low dilution cultures at similar bacterial density (*, P<0.05).
Fluorescence was normalized to constitutive controls at 6x108 cfu/mL. E) After 31 hours
post-injection, QS salmonella express GFP only within distinct bacterial colonies. Lac
salmonella express GFP throughout the entire tissue regardless of bacterial concentration.
F) Area fraction of tissue with GFP expression over time. Tissue infected with QS
Salmonella showed a significant difference in area with “on” bacteria after 40 hours (*,
P<0.05). White bounding boxes indicate the area analyzed for a representative tissue at
53 post-injection. Scale bars are 100µm.
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Figure 3.4 GFP expression of QS Salmonella within tumor-bearing mice. A)
Colonies of QS and constitutive Salmonella (red) in 4T1 tumors and associated GFP
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between Salmonella and GFP. Scale bars are 100µm. B) GFP expression dependence on
Salmonella density. The percentage of QS Salmonella colonies expressing GFP at all
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(*, P<0.05). The fraction of constiutive colonies expressing GFP was statistically greater
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P<0.05).
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Figure 3.5 Density Optimization of GFP Expression A) Profile of GFP expression in
relation to bacterial density where ρcrit is the critical density at which GFP expression
occurs, and σ represents how sensitive the quorum-sensing switch is to changes in density
B) Sigmoidal function modeling the percentage of GFP expression in relation to
Salmonella density in a 125 pixel radius circle. Eq. 1 was used to fit the model to the
experimental data and calculated ρcrit = 0.41 (4.97x1010 cfu/g) and σ = 0.23 (2.72x1010
cfu/g). C) The amount of Salmonella was counted for increasing circle sizes surrounding
each colony. D) The standard errors of the two parameters, ρcrit and σ, in Eq. 1 were
minimized at a circle size of radius 125 pixels. E) The values of ρcrit and σ for increasing
circle radius.
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57#

A

AI-1 Concentration

r
r

r
r

r=0

= colony of interest
= neighboring bacteria

B

C

2

r=40µm r=81µm
r=121µm

ρ=9x10 cfu/g
ρ=6x1010 cfu/g
10

1

0
0

80
r (µm)

ρ=3x1010 cfu/g
ρ=1.2x109 cfu/g
160

C/Cq

C/Cq

2

r=ravg

1

0
0

r=161µm

6
12
ρ (×1010 cfu/mL)
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58#

A 161 OFF

C/Cq=1.38
i

rq (µm)

B

ii

C/Cq=1.00

81

ON
0

130

rq (µm)

B

0

97

6
10.2 ρ=5.81x1010 r=83µm
ρ (×10 cfu/mL)
10

iv

ρ=5.53x1010 r=106µm

C/Cq=0.98

iii

iii
ii

C/Cq= 0.71
iv

i
64
4.2

5.1
6
ρ (×1010 cfu/mL)

ρ=5.53x1010 r=108µm

ρ=4.55x1010 r=106µm

Figure 3.8 Predictive capability of AI-1 mathematical model A) Critical average
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3.3 Discussion
Administering Salmonella with the ability to change gene expression in a densitydependent manner has the ability to improve the targeting capability of bacterial cancer
therapy and reduce systemic toxicity. We have shown that Salmonella integrated with a
quorum-sensing trigger turns on protein expression in high-density colonies within
tumors while remaining off low-density colonies.

In addition, the likelihood of GFP

expression of high-density colonies increased as the radial distance of neighboring
Salmonella decreased. A mathematical model of AI-1 concentration predicted the
likelihood of GFP expression in 93% of QS colonies found in tumor tissue based on
density and radial distance from adjacent Salmonella. In contrast, when Salmonella was
administered with a constitutive trigger, protein expression was observed in low-density
colonies and individual Salmonella with no surrounding neighbors.

These results

demonstrate that a bacterial cancer therapy with a QS triggering system will prevent
therapeutic protein release in healthy tissue and maximize therapeutic effect in tumors.

The density of QS Salmonella in livers and the critical density needed to trigger the QS
system render the possibility of gene expression almost impossible in healthy tissue.
While no Salmonella were seen in livers by immunohistochemistry, approximately 2x104
cfu/g of Salmonella was observed in plating experiments (Figure 3.3B), 2 million-fold
lower than the density at which the QS system turned on expression in tumor tissue
(Figure 3.5B). Theoretically, if all the Salmonella found in the liver were located within
a 161.3µm radial circle, the density would be 4.8x1010 cfu/g, which would still be below

60#

the critical density (ρcrit = 4.97x1010 cfu/g) to turn on the QS system. Mathematical
modeling predicts that at this density, Salmonella would need to be at a radial distance
less than 82µm apart for expression to occur (Figure 3.8A). No QS colony at 4.8x1010
cfu/g in tumor tissue had an average radial density less than 82µm. Protein expression
was seen in 45% of constitutive Salmonella at the lowest possible detectable density in
tumor tissue (Figure 3.4B). Constitutive expression of toxic proteins in livers or other
healthy organs, even at low numbers, has the potential for detrimental effects on the
patient. In comparison, only 0.06% of QS Salmonella exhibited protein expression at low
densities in tumor tissue (Figure 3.4B).

This data suggests that none of the QS

Salmonella in the liver expressed GFP.

The sensitivity of this density-dependent switch suggests that QS Salmonella have the
ability to treat undetected metastatic legions and remain off in surrounding healthy tissue.
The QS system turns on at a density of 41% coverage (4.97x1010 cfu/g) in tumor tissue.
In previous work, Salmonella accumulate in liver metastases at a density of 44% (Ganai
et al., 2011), suggesting that all colonies would be active. In the surrounding hepatic
parenchyma, Salmonella colonies accumulate with an average density of 0.5% (Ganai et
al., 2011) and would all be inactive. The average metastases in this previous study had a
cross-sectional area of 5.3mm2, which is 66 times greater than 0.08mm2 (Figure 3.5E),
the region large enough for sufficient neighbors to turn on QS expression.

Diffusion and bacterial spatial distribution within tumors plays an important role in
triggering QS system. QS Salmonella turn on protein expression at densities of 108
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cfu/mL in flasks (Figure 3.2B), but mixing ensures that AI-1 is well distributed and not
detected by diffusion. In tumor tissue, however, the QS switch turned on at densities of
4.97x1010, almost 500-fold higher than flasks (Figure 3.5B). The increase in density was
caused by the distance necessary for AI-1 to diffuse throughout the tissue once the system
was turned on. At densities above 5.28x1010 cfu/g, protein expression was dependent on
bacteria being packed closer than 103 µm to each other (Figure 3.7B).

Mathematical

modeling predicted that as the density of bacteria decreased, the average radial distance
of the surrounding neighbors must decrease as well for the QS switch to turn on (Figure
3.8A). Decreasing the distance between bacteria decreases the distance AI-1 must travel
between individual bacteria and increases the overall AI-1 concentration in a bacterial
cluster. Below a critical threshold of 5.28x1010 cfu/g, however, there are not enough
individuals producing AI-1 to turn on expression, no matter how tightly packed they are
(Figure 3.6B).

QS Salmonella have other important advantages over other proposed mechanisms of
bacterial drug delivery. No autoinducer was used to induce expression of GFP after
colonization. Previous strategies with autoinducers are problematic, as an autoinducer
must overcome both the clearance from the body and diffusion limitations far from
vasculature. Without the need for an autoinducer, the system is not reliant on the presence
of a small molecule to maintain therapeutic expression levels. Persistent gene expression
was observed in tumor tissue as late as 24 days post injection. From a clinical standpoint,
this means fewer injections for the patient and a quicker therapeutic effect.
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Salmonella integrated with a robust QS triggering system opens up the possibility for the
use of aggressive therapeutic proteins, previously deemed too toxic for both systemic and
bacterial drug delivery. Potential therapeutics such as Staphylococcus aureus αhemolysin kill multiple cancer cells quickly (St Jean et al., 2014; Swofford et al., 2014),
but might be too toxic if delivered to healthy tissue. Salmonella integrated with a QS
switch could prevent expression in healthy tissue, despite the low-level bacterial
accumulation in healthy tissue (Figure 3.3B). In addition, QS Salmonella could maintain
therapeutic expression levels due to continuous production. Overall, the QS system
creates a robust switch that will allow for targeted bacterial drug delivery to tumors and
metastases without the need for an external inducer while minimizing the risk of
potentially harmful drugs reaching healthy tissue.

3.4 Materials and Methods
3.4.1 Bacterial strains and plasmids
The QS architecture used in this study has the luxI, luxR, and gfp genes under one side of
the PluxI bidirectional promoter to create an on/off switch (Figure 3.1B). Two plasmids
were created that contained the green fluorescent protein GFPmut3 under the control of
either the constitutive lac promoter or a quorum sensing circuit. These plasmids also
contained the gene encoding for aspartate-semialdehyde dehydrogenase (asd) that allows
for plasmid retention in the nonpathogenic msbB-, purI-, xyl-, asd- Salmonella strain,
VNP200010. Plasmid cloning was performed in Escherichia coli DH5α (Invitrogen,
Carlsbad, CA, USA) and transformed into VNP200010. All restriction enzymes were
purchased from New England Biolabs (Ipswich, MA, USA).
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QS-GFP was created by

PCR amplifying the luxI gene out of pACluxInv, a gift from Dr. Voigt (University of
California,

San

Francisco,

CA),

using

the

forward

primer

5’-

TTCGGCCGGAATAAACGCAAG-3’ (EagI site underlined) and the reverse primer 5’GCACATGTATCTTGAATCATTCCAT-3’ (PciI site underlined) and subcloned into
PluxI-Gfpmut3-luxR, a gift from Dr. Sun (University of Massachusetts Amherst, MA)
using the EagI and PciI sites. The asd gene was PCR amplified from pYA3332 (Vion)
using the forward primer 5’-GCTCATGACGTACGTTTTCGTTCCATTG-3’ (BspHI site
underlined)

and

the

reverse

ATACTAGTATCTGCGTTTACTCTTGTATTACG-3’

primer
(SpeI

site

underlined)

5’and

subcloned into pQSGFPmut3 using BspHI and SpeI sites to create QS-GFP.

placGFPmut3-ASD was created by PCR amplifying the asd gene from pYA322 using the
forward

primer

underlined)

5’-GCGAATTCGTACGTTTTCGTTCCATTG-3’
and

the

reverse

(EcoRI

primer

site
5’-

ATGACGTCATCTGCGTTTACTCTTGTATTACG-3’ (AatII site underlined). Asd was
subcloned into placGFPmut3, a gift from Dr. Sun, to create a constitutive control.

3.4.2 Expression of QS promoter using fluorimetry
QS-GFP and a constitutive control were grown overnight in 3mL cultures and diluted to
105 cfu/mL in 20mL of LB media. Every hour, the optical density (OD) of a 200µL
aliquot was measured at 600nm.

Fluorescence was measured using an excitation

wavelength of 465nm and an emission wavelength of 505nm.
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3.4.3 Measurement of QS expression levels based on changes in culture conditions
QS-GFP and constitutive controls were grown from a colony in 3mL cultures to an OD of
0.1. An aliquot was diluted to 105 cfu/mL in 20mL of LB media (Diluted Low) while the
original 3mL culture was allowed to continue growing. After the original 3mL culture
reached an OD of 1.0, another aliquot was diluted to 105 cfu/mL in 20mL of LB media
(Diluted High). Every hour, the optical density and fluorescence of both cultures were
measured.

3.4.4 Measurement of protein expression within in vitro tumor tissue
A microfluidic tumor-on-a-chip device containing cancer cells was used to measure
bacterial protein expression in tumor tissue. Human LS174T colon carcinoma cells were
maintained in Dulbecco’s Modified Eagles Medium (DMEM) containing 10% fetal
bovine serum (FBS; Sigma-Aldrich) at 37 °C and 5% CO2. Multicellular tumor spheroids
were formed by seeding 2.5 x 104 cells/ml on poly(2-hydroxyethyl methacrylate; SigmaAldrich) coated T25 flasks for 12-14 days. The methacrylate coating prevents cell
adhesion to the flask surface. Devices were fabricated using soft lithography techniques
described previously (Toley et al., 2011; Toley and Forbes, 2012; Walsh et al., 2009).
Prior to inserting cells, devices were sterilized by flushing with 70% ethanol, followed by
phosphate buffered saline (PBS) to remove air and residual ethanol. Spheroids were
inserted into the 1000µm x 300µm x 150µm cuboidal chambers by trapping them in the
filters at the distal ends (Walsh et al., 2009). The medium flow rate was set to 3.0 µl/min,
which is similar to the average linear velocity in tumor vessels (1.7 mm/sec) (Forbes et
al., 2003). Devices were incubated for 24 hours at 37°C in an enclosed, humidified
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environment on the microscope stage. pH was maintained by continuous perfusion of
HEPES (25 mM) buffered DMEM.

QS-GFP and constitutive controls were grown overnight, centrifuged and re-suspended in
DMEM with 10% FBS at a density of 105 CFU/mL. Bacteria-containing medium was
administered to devices for 1 hour, stopped, and switched to bacteria-free medium.
Images of each chamber were acquired for 72 hours (Olympus, Center Valley, PA). To
capture an entire chamber (1000 µm x 300 µm), 2 images (867.15µm x 660.68µm each)
obtained at 10x were tiled together using a macro in IPLab (BD Bioscience, Rockville,
MD). Transmitted light and green fluorescence images were captured at 1-hour intervals,
using 470nm excitation and 525nm long pass emission filters (Chroma, Rockingham,
VT). ImageJ (NIH Research Services Branch) was used to quantify green fluorescence.
Temporal fluorescence profiles were measured for each tissue as a function of time and
subtracting background fluorescence. Area fraction of tissue with GFP expression above
a constant threshold was measured across all images and divided by the total area of
tissue. The zero time point was set to be immediately after bacterial inoculation.

3.4.5 Tumor formation in murine models
4T1 mammary carcinoma cells (American Tissue Type Collection, Manassas, VA) were
grown in RPMI-1640 with 10% FBS. Tumors were formed by subcutaneously injecting
50,000 4T1 cells, suspended in PBS, into the flank of BALB/c mice at 8 weeks of age.
Caliper measurements were taken regularly to monitor tumor growth. Tumor volume
was calculated by (width)2(length)/2. Implanted tumors were allowed to grow until
volumes reached 2000mm3. All animal procedures were approved by Baystate Medical
66#

Center Institutional Animal Care and Use Committee (IACUC).

Experiments were

conducted in accordance with the National Institute Health (NIH) guidelines for care and
use of laboratory animals.

3.4.6 Administration of Salmonella
A dose of 2x106 colony forming units (CFU) mid-log phase VNP200010, transformed
with either pQSGFPmut3-ASD or pLacGFPmut3-ASD, was suspended in 100µl PBS and
injected intravenously into mice with size-matched tumors of 500mm3 via the tail vein.
Mice were sacrificed when tumors reached 2000mm3 for tissue collection, which took
place 2-3 weeks after bacterial injection. Tumor and liver samples were cut in half. One
half was fixed in 10% formalin and embedded in paraffin, while the other half was
minced in saline and plated. LB agar plates were counted after growth at 37ºC for 24 hr.

3.4.7 Immunofluorescence labeling
Salmonella and GFP were identified by immunofluorescence.

Five micron thick

equatorial sections were cut from excised tumors and livers, deparaffinized and
rehydrated. Antigen retrieval was performed on each tissue by soaking sections in
sodium citrate buffer (10mM Sodium Citrate, 0.05% Tween 20, pH 6.0) for 20 minutes.
Sections were then blocked with protein block (Agilent Technologies, Santa Clara, CA)
for 20 minutes. Sections were probed with a 1:200 dilution of rabbit anti-Salmonella
(Abcam, Cambridge, MA) and a 1:50 dilution of goat anti-GFP (Abcam) overnight,
followed by incubation with a 1:200 dilution of Alexa Fluor 546-conjugated donkey antirabbit antibody and a 1:50 dilution of Alexa Fluor 488-conjugated donkey anti-goat
antibody at room temperature for 1 hour. Processed tissue sections were counter-stained
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with VECTASHIELD® Mounting Media with DAPI (Vecta Labs, Burlingame, CA),
mounted with coverslips, stored at 4ºC and protected from light.

3.4.8 Image acquisition
Images were acquired using epifluorescent microscopy techniques described earlier using
a 10X objective. Salmonella, labeled with Alexa 546, were identified using 546nm
excitation and 590nm long pass emission filters (Chroma). GFP, labeled with Alexa 488,
were identified using 470nm excitation and 525 long pass emission filters (Chroma).
DAPI counterstaining was identified with a UV excitation filter set (Chroma). Images of
entire tissues were captured by tiling 250-650 adjacent 867.15µm x 660.68µm frames
using a macro in IPLab.

3.4.9 Bacterial and GFP distribution analysis
Salmonella and GFP distribution was quantified using imageJ. Red-fluorescence and
green-fluorescence were thresholded and converted into binary images to identify regions
(pixels) that contained Salmonella and GFP. Artifacts were manually eliminated based
on morphology and fluorescence intensity from each individual tile comprising the entire
tissue. Individual binary tiles were then reconstructed to create red-fluorescence and
green-fluorescence images for the entire tissue. The number of Salmonella colonies and
their center of mass was determined by analyzing each binary image using particle
analysis in ImageJ. Different densities of Salmonella surrounding each colony were
determined by counting the number of red-fluorescence pixels in increasing circle sizes,
ranging from a 10 to 200-pixel radius, surrounding each center of mass. An individual
red pixel was assumed to be equal to 1 Salmonella bacterium.
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Each colony was

considered co-localized with GFP if a green-fluorescence pixel was within a 25-pixel
radius circle surrounding the center of mass. This process assigned a binary result
regarding the presence of GFP for each colony: a value of 1 if GFP was present or a 0 if
not present.

A sigmoidal function was used to fit the percentage of colonies with GFP at each density
for various circle sizes (Eq. 7). The function consisted of two parameters, ρcrit, the
critical density at which GFP expression occurs, and σ, the robustness of the QS switch.
The data was fit using nonlinear regression in MATLAB to calculate the two parameters
and their standard error for various circle sizes. An optimal circle size was determined
by minimizing the standard error of the two parameters. The average radial distance of
all neighboring colonies to the colony of interest was determined by determining the
number of Salmonella in a 25pixel radial annulus with varying distances from the colony
of interest. The radial distance of the annulus to the center of the colony was assigned to
each Salmonella pixel located within it. The weighted average of all radial distances of
neighboring bacteria was then assigned to each colony of interest.

3.4.10 Mathematical modeling of AI-1 diffusion
A mathematical model was used to interpret the concentration of AI-1 in tumor tissue
(Eq. 8). The model consisted of a single partial differential equation that balanced AI-1
production based on density with diffusion. The optimized parameters determined in Eq.
1 were used to model GFP production in relation to density.

This model had an

analytical solution (Eq. 9) that was dependent on distance, time, density, and a
dimensionless parameter, Q, which related AI-1 production at maximum density to
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diffusion. This analytical solution was assumed to be at steady-state for further analysis
(Eq. 10). The value of Q was determined from the immunofluorescence data by nonlinear optimization.

Its value was adjusted until the model could predict the GFP

expression in the maximum amount of colonies, based on the density and average radial
distance of all neighboring colonies to the colony of interest.

3.4.11 Statistical analysis
For all in vitro work, data are reported as means with error bars representing standard
errors of the mean. Hypotheses were tested using Student’s t-test with a significance
level indicated by P<0.05. For all in vivo colony GFP expression work, data are reported
as means with error bars representing a 95% Clopper-Pearson binomial confidence
intervals. Hypotheses were tested using a Fisher’s exact test with a significance level
indicated by P<0.05. Parameters from Eq. 7 are reported with error bars representing the
asymptotic standard error estimated using the Jacobian matrix and weight function from
the nonlinear regression.
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CHAPTER 4
INTEGRATION OF THE QUORUM-SENSING SWITCH WITH
STAPHYLOCOCCUS ALPHA-HEMOLYSIN

4.1 Introduction
Bacterial cancer therapy has the potential to overcome many of the challenges associated
with current chemotherapy, including transport limitations, systemic delivery, and
reduced susceptibility of quiescent tumor cells, due to the inherent ability of bacteria to
localize in both tumors and metastases (Forbes, 2010). Despite this, many challenges lie
ahead before an optimized bacterial therapy will be realized in the clinic.

Native

bacterial toxicity has been shown to regress tumors and increase survival, but bacteria
alone are unable to completely eliminate tumors (Chen et al., 2009; Jia et al., 2007; Lee et
al., 2008; Low et al., 1999; Luo et al., 2001; Nagakura et al., 2009; Pawelek et al., 1997;
Thamm et al., 2005; Theys et al., 2006; Zhao et al., 2007). In addition, low-level
bacterial accumulation in healthy tissue prevents constitutive expression of an anti-cancer
drug, reducing the efficacy of a bacterial therapy over standard chemotherapeutics. The
research described in this thesis has pushed bacterial cancer therapy closer to the clinic by
overcoming these challenges.

In the first part of this work, a novel bacterial cancer therapeutic, Staphylococcus alphahemolysin (SAH), was discovered to secrete from anticancer bacteria and rapidly kill
cancer cells. SAH was shown to be effective against multiple cancer cell types, including
two triple-negative breast cancer cell lines. While incredibly effective, SAH could prove
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lethal to patients if small amounts of bacteria within healthy tissue were to secrete the
protein. The second part of this work aimed to solve this problem by creating a tumorspecific triggering system, which has the capability to both reduce systemic toxicity and
allow for the use of more aggressive therapeutics, such as SAH, because of enhanced
drug targeting. Therapeutic Salmonella, integrated with the lux quorum-sensing system
from Vibrio fischeri, were able to selectively trigger protein expression within highdensity colonies in tumor tissue while exhibiting little to no expression at lower densities.

Individually, each part of this thesis provide a necessary framework for improving upon
bacterial cancer therapies. The logical next step would be to combine the aggressive
therapeutic SAH with the quorum-sensing system.

We hypothesized that QS-SAH

Salmonella would only secrete SAH at high densities.

To test this hypothesis, we

integrated the lux QS system with SAH and transformed this system into VNP200010.
SAH production in response to density was measured by western blot. An integrated
assay involving both bacterial and mammalian cell culture was used to screen the
translation, secretion, and killing ability of SAH in response to the bacterial density in
culture. Cell viability was determined using a cell viability assay. Salmonella integrated
with the QS-SAH system were injected in tumor-bearing mice to quantify tumor volume
over time.
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4.2 Materials and Methods
4.2.1 Bacterial strains and plasmids
QS-SAH Salmonella was created by PCR amplifying the SAH gene out of the genome of
Staphylococcus

aureus

strain

MW2,

using

the

forward

primer

5’-

TAGCTAGCTCGTTTAAAAAAATAGAAG-3’ (NheI site underlined) and the reverse
primer 5’-ATCCTGCAGGTTAATTTGTCATTTCTTCT-3’ (SbfI site underlined). SAH
was then subcloned into pBAD_SAH using the NheI and SbfI sites to create pQS-SAH.
The pQS-SAH plasmid consists of the high copy PUC origin, the ampicillin resistance
gene, the lux QS system, and the asd gene, used for selection pressure in the asdVNP200010 Salmonella strain. pQS-SAH was then transformed into VNP200010. pQSGFP was previously designed as outlined in Chapter 2.

4.2.2 Supernatant and lysis collection of QS-SAH
QS-SAH Salmonella was grown overnight in 3mL cultures and diluted to 105 cfu/mL in
200mL of LB media. After the culture reached an OD of 0.01, a 5mL aliquot was
removed every half an hour. The optical density was measured at 600nm on a µQuant
Universal Microplate Spectrophotometer (Bio-Tek Instruments, Winooski, VT).
Bacterial cells were then pelleted by centrifugation and separated for supernatant
extraction. Supernatant fractions were purified with a 0.22 µm-filter and concentrated
10X by centrifugal ultrafiltration (Millipore, Billerica, MA). Eventual 10X dilution of
dilution of the concentrated supernatant was considered a co-culture equivalent
concentration. Pellets were resuspended and incubated for 30 min in 500 mL water
containing 1 halt protease inhibitor cocktail (Thermo Fisher Scientific), 12.5 units/mL of
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DNAaseI (Thermo Fisher Scientific), and 25mg/mL of lysozyme (Thermo Fisher
Scientific). After incubation, pellets were transferred to 2 mL centrifuge tubes with 600
mm glass beads. These samples were alternately vortexed for 1 min and incubated on ice
for 1 min, for 10 cycles. One milliliter of water was then added, vortexed briefly, and
centrifuged for 3 min. The lysis supernatant was removed without disturbing the glass
beads. pBAD-SAH supernatant controls were collected by the methods outlined in
Chapter 1.

4.2.3 Western blot analysis
Supernatant fractions from each OD were boiled with 4X Laemmli reducing buffer
(Boston BioProducts, Ashland, MA) for 5 min and run on SDS-PAGE for 45 min at
200V. Proteins were transferred to nitrocellulose membranes that were blocked with 5%
milk in tris-buffered saline containing 0.2% tween-20 (TBST) for 1 hour at room
temperature.

SAH samples were probed with 1:1,000 sheep anti-SAH polyclonal

antibody (Abcam, Cambridge, MA) overnight at 4ºC, washed three times in TBST,
proved with a 1:1,000 HRP-conjugated donkey anti-sheep polyclonal antibody (R&D
Systems) for 1 hour at room temperature, and washed three times in TBST. To visualize
and image the immunoblot, 4-chloro-1-naphthol/3,3’-diaminobenzidine (CN/DAB);
(Thermo Fisher Scientific) was used for chromogenic detection of HRP.

4.2.4 Assay of protein efficacy
MCF-7 human mammary carcinoma cells (American Tissue Type Collection, Manassas,
VA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM); (Sigma-Aldrich,
St. Louis, MO) containing 10% Fetal Bovine Serum (FBS); (Atlanta Biologicals,
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Lawrenceville, GA) at 37ºC and 5% CO2. Cells were seeded at 7,500 cells/well into 96well plates and allowed to adhere to the culture surface for 24 hours. The media was
aspirated and replaced with treatment media consisting of 90% DMEM/FBS and either
10% phosphate-buffered saline (PBS) or bacterial supernatants from increasing densities.
This dilution allowed for protein levels equivalent to direct co-culture without having
bacteria in mammalian culture. Each treatment media application was replicated in eight
wells.

After 1 hour, cell viability was measured by assay with 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolum (MTS); (Promega, Madison,
WI). Treatment medium was replaced with 100µL DMEM/FBS plus 20µL MTS reagent
and incubated for 1 hour at 37ºC for color development. Absorbance was measured at
490nm (Bio-Tek Instruments, Winooski, VT). Relative survival values are reported as
measured absorbance normalized by PBS controls.

4.2.5 In vivo efficacy of QS-SAH
4T1 mammary carcinoma cells (American Tissue Type Collection, Manassas, VA) were
grown in RPMI-1640 with 10% FBS. Tumors were formed by subcutaneously injecting
50,000 4T1 cells, suspended in PBS, into the flank of BALB/c mice at 8 weeks of age.
Caliper measurements were taken regularly to monitor tumor growth. Tumor volume
was calculated by (width)2(length)/2. Implanted tumors were allowed to grow until
volumes reached 2000mm3. All animal procedures were approved by Baystate Medical
Center Institutional Animal Care and Use Committee (IACUC).

Experiments were

conducted in accordance with the National Institute Health (NIH) guidelines for care and
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use of laboratory animals. A dose of 2x106 colony forming units (CFU) mid-log phase
VNP200010, transformed with either pQS-GFP or pQS-SAH, was suspended in 100µl
PBS and injected intravenously into mice with size-matched tumors of 500mm3 via the
tail vein. Mice were sacrificed when tumors reached 2000mm3 for tissue collection,
which took place 2-3 weeks after bacterial injection.

4.3 Results
4.3.1 Density dependence on the concentration of SAH
SAH was only present in the supernatant of QS-SAH Salmonella at very high densities
(Figure 4.1).

SAH was detectable once Salmonella grew to densities higher than

1.16x109 cfu/mL (Figure 4.1A). Below this critical threshold, no presence of SAH was
detected. QS-SAH Salmonella secreted 13% the concentration of SAH at 1.16x109
cfu/mL compared to pBAD-SAH supernatant induced at a density of 2.5x108 cfu/mL
(Figure 4.1B).

QS-SAH lysis had 40% the concentration of SAH as pBAD-SAH lysis

controls.

4.3.2 Efficacy of QS-SAH Salmonella on cancer cell death
SAH secreted from Salmonella at high densities did not show a significantly decrease cell
death compared to PBS controls (Figure 4.2). pBAD-SAH supernatant controls reduced
cell viability to 22% after one hour, while supernatant from QS-SAH Salmonella at
densities at 1.16x109 cfu/mL did not reduce cell viability at all. There was also no effect
on cell viability as the density of Salmonella increased.
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4.3.3 Effect of QS-SAH Salmonella on in vivo murine models
Mice administered with QS-SAH Salmonella did not show a significant decrease in
tumor volume compared to QS-GFP Salmonella controls (Figure 4.3).

4T1 tumors

exposed to QS-SAH and QS-GFP Salmonella both had doubling times of 7.3 days. After
the administration of Salmonella, mice did not exhibit any signs of toxic side effects.
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Figure 4.1 Density dependence of QS-SAH A) Western blots of lysate and supernatant
from QS-SAH and pBAD-SAH. SAH is secreted from QS-SAH at densities of OD=2.3
(1.15x109 cfu/mL). B) Relative protein expression was quantified using densitometry.
The QS system only secreted 13% the amount of SAH secreted from the pBAD system
after induction at 2.5x108 cfu/mL. Values were normalized to the supernatant of pBADSAH.
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Figure 4.2 Density dependence of QS-SAH on cell viability. QS-SAH supernatant
from increasing densities had no effect on cell viability compared to PBS controls.
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Figure 4.3 Effect of SAH secreted by QS-SAH on in vivo tumor volume. QS-SAH
did not affect volume of subcutaneous 4T1 tumors compared to QS-GFP controls. 4T1
tumors infected with either QS-SAH or QS-GFP both had doubling times of 7.3 days.
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4.4 Discussion
Salmonella expressing SAH integrated with a QS expression switch only initiated SAH
expression at very high densities in vitro. The reduced concentration of SAH was not
enough to reduce cell viability of cancer cells in vitro. In addition, QS-SAH did not
reduce tumor volume in mice. SAH produced by QS Salmonella was only 13% of the
amount produced by the pBAD-SAH controls, which induced expression in the presence
of arabinose. These results show that a VNP200010 bacterial cancer therapy integrating
SAH with a QS triggering system did not produce enough SAH to reach a therapeutic
effect both in monolayer culture and in murine tumor models.

SAH was most likely unable to reduce tumor volume in mice because of the low SAH
expression produced. In chapter 2, SAH from pBAD Salmonella was shown to reduce
cell viability by over 88% in just six hours (Figure 2.6A), but this therapeutic effect
quickly dropped if secreted SAH was diluted 10-fold. At a 1:10 dilution, cell viability
only reduced by 41%, 2-fold less than the non-diluted sample (Figure 2.6A). SAH from
QS Salmonella, at high densities of 1.16x109, only produced 13% of the pBAD-induced
sample (Figure 4.1A), similar to the 1:10 diluted pBAD-SAH sample. This would reduce
the therapeutic effect of SAH.

Because the QS system was unable to produce enough SAH, SAH would benefit from a
different expression system to induce enough for a therapeutic effect. Inducing SAH
using the pBAD system would be the first obvious choice since we have shown its
efficacy in previous experiments (Chapter 2). Arabinose has also already been shown to
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control gene expression in tumors (Loessner et al., 2007; Nguyen et al., 2010) and
infracted myocardium (Le et al., 2011). Due to the need for high concentrations of SAH
for therapeutic effect, a system integrating both the pBAD and QS system created in our
lab could be used to amplify the production of SAH and trigger the expression of SAH in
regions of tissue unreachable by arabinose alone (Dai et al., 2012). Other inducible
systems using salicylate (Royo et al., 2007) or IPTG could also provide a stronger
expression system that would boost the concentration of SAH within tissue.

The QS system, despite its inability to produce therapeutic concentrations of SAH, still
has the potential to treat cancerous tissue if combined with another therapeutic protein.
PEA, for example, was another protein discovered from the toxin screen that was
secreted from Salmonella and reduced the cell viability. Secreted PEA reduced cell
viability 6-fold compared to an empty vector control (Figure 2.3A) after a 72-hour
exposure. Furthermore, pure PEA as low as 50ng/mL was able to reduce cell viability
even after a five-day exposure (Figure 2.6B). SAH secreted from Salmonella produced
concentrations of approximately 500ng/mL (Figure 2.4B), suggesting that PEA could be
secreted at similar amounts using the pBAD system. If the QS system were to secrete
10% of that amount, it could potentially still produce a therapeutic effect with PEA.
Results with the toxin screen suggest that many more potential proteins, previously
considered too dangerous for cancer therapy, should be reevaluated in the context of the
QS delivery system.
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CHAPTER 5
IMPACT
This work has solved two critical problems associated with bacterial cancer therapy: 1)
the discovery of a therapeutic drug that can be expressed by bacteria for the treatment of
cancer and 2) a gene triggering strategy that will prevent expression within healthy tissue.
Bacterial cancer therapy holds great promise as a clinical alternative to chemotherapy due
to the inherent ability of bacteria to localize within cancerous tissue.

However,

colonization within tumors alone is not enough to eliminate cancerous tissue. For the
first time, we have discovered SAH as a potential therapeutic protein for bacterial cancer
therapy, due to its ability to secrete out of nonpathogenic Salmonella in concentrations
that rapidly kill cancer cells. The toxin also indiscriminately kills multiple types of
cancer cells because it forms pores in cellular membranes and does not require
endocytosis to be effective. Using our toxin screen, we have also discovered PEA as a
potential therapeutic, since it also secretes and kills cancer cells, although at a much
slower rate than SAH.

This screen suggests that the hundreds of bacterial toxins

considered too toxic for consideration should be reevaluated in the context of bacterial
therapy.

This work has also demonstrated, for the first time, a QS-gene-triggering strategy that
only switches on expression in high-density colonies within tumors without the need of
an external autoinducer. Previous strategies with autoinducers are problematic, as an
autoinducer must overcome both the clearance from the body and diffusion limitations far
from vasculature.

Another distinct advantage is that the QS system exhibits persistent
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gene expression once the density is above a critical threshold. Without the need for an
autoinducer, the system is not reliant on the presence of a small molecule to maintain
therapeutic expression levels. From a clinical standpoint, this means fewer injections for
the patient and a quicker therapeutic effect. Finally, due to the density of bacteria being
significantly lower than the critical density needed for QS gene expression, the small
amount of bacteria in healthy tissue remain off. This will be critical if the QS system is
connected to an aggressive therapeutic that only requires a small concentration in healthy
tissue to harm the patient. In conclusion, coupling the QS system developed in this thesis
with an aggressive protein drug similar to SAH has the potential to be more effective than
standard chemotherapeutics, due to its ability to target expression only within tumors.
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